Compare Incyte Corporation (INCY) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.86 (market cap $3.56B). The key difference: Incyte Corporation is far larger — about 6.4× GraniteShares 2x Long NVDA Daily ETF's market cap, and GraniteShares 2x Long NVDA Daily ETF is more actively traded (9,740,643 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| INCY | NVDL | |
|---|---|---|
Market Cap | $22.85B | $3.56B |
Volume | 1,927,029 | 9,740,643 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $43.02 |
52-Week Low | $83.80 | $21.76 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $37.28, down 5.79% in the last session. Technical indicators show a bullish bias with moving averages supporting upward momentum while oscillators remain neutral. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to dominate AI chip markets with strong earnings performance. Recent news highlights ongoing M&A activity in the ETF space and continued AI sector strength.
The outlook remains positive given NVIDIA's market leadership and AI growth trajectory, though leveraged ETF structure introduces volatility risks. Key opportunities include continued AI adoption and NVIDIA's execution, while risks involve leverage decay and sector concentration. Current technical setup suggests potential for recovery toward resistance levels near $39-41 if bullish momentum resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
